NCT06264622View on ClinicalTrials.gov

ABG+/GarlACE Effects on Cardiovascular Risk Factors in Subjects With Grade I Hypertension

NARecruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

February 26, 2024

Primary Completion Date

October 31, 2024

Study Completion Date

December 31, 2024

Conditions
Hypertension
Interventions
DIETARY_SUPPLEMENT

Low dose

2 tablets per day during the morning for 12 weeks.

DIETARY_SUPPLEMENT

High dose

2 tablets per day during the morning for 12 weeks.

DIETARY_SUPPLEMENT

Placebo

2 tablets per day during the morning for 12 weeks.

Trial Locations (1)

25198

RECRUITING

University of Lleida, Lleida

All Listed Sponsors
collaborator

Pharmactive Biotech Products S.L.U

INDUSTRY

lead

Universitat de Lleida

OTHER

NCT06264622 - ABG+/GarlACE Effects on Cardiovascular Risk Factors in Subjects With Grade I Hypertension | Biotech Hunter | Biotech Hunter